October 4, 2018—Teleflex announced that it has acquired Essential Medical, Inc., a privately held company based in Exton, Pennsylvania, that developed and commercialized the Manta vascular closure device.
The Manta device is designed for closure of large-bore arteriotomies after procedures utilizing devices or sheaths ranging in size from 10 to 18 F, with maximum outer diameters up to 25 F.
Teleflex advised that the Manta device is not approved for sale or distribution in the United States. The company anticipates FDA premarket approval of the Manta device in 2019.
Manta has received European CE Mark approval. In the CE Mark study, the Manta device demonstrated rapid and reliable hemostasis with its resorbable collagen-based technology and complication rates that were noninferior to surgical and suture-based closure methods. The study was published in March 2017 by Nicolas M. Van Mieghem, MD, et al in Journal of the American College of Cardiology: Cardiovascular Interventions.
advertisement
Related Articles
Top 5 Articles From October 2018
Tumor Boards in Interventional Oncology
A multidisciplinary discussion of the approach to treatment for four patients with cancers of varying origins and severities.
With Ghassan K. Abou-Alfa, MD; Justin D. Blasberg, MD; Frank C. Detterbeck, MD, FACS, FCCP; Dimitris Filippiadis, MD, PhD, EBIR; Ryan Hickey, MD; Howard S. Hochster, MD; Zeljka Jutric, MD; Alexis Kelekis, MD, PhD, EBIR, FSIR; Maureen P. Kohi, MD, FSIR; Alexander Lam, MD; Robert J. Lewandowski, MD, FSIR; Areo Saffarzadeh, MD, MS; Mansi R. Shah, MD; Ronald F. Wolf, MD; Emi J. Yoshida, MD; and Etay Ziv, MD, PhD
Commentary: Staying on Course
Obtaining the highest level of evidence in interventional oncology requires that we stay on course and strive for positive prospective randomized trials.
By Nadine Abi-Jaoudeh, MD
Applying Evidence in Interventional Oncology
By Nadine Abi-Jaoudeh, MD; and Julius Chapiro, MD
AI in IO: Big Data, Outcome Repositories, and Clinical Applications
How the expanding health care applications of artificial intelligence may be incorporated to improve interventional oncology processes and care.
By Brian Letzen, MD, MS; and Raul N. Uppot, MD
Experience With Philips SymphonySuite Building My Lab
Harmonizing products and services for long-term success.
With Elias Kassab, MD; and Phil Hemstreet, MD
Top 5 from CIToday's Current Issue
CT Assessment Before TMVR
By Moderator: Dee Dee Wang, MD, FACC, FASE, FSCCT
Panel: Mayra Guerrero, MD; and Marco Barbanti, MD
Challenging Cases: What Would You Do?
By Ted E. Feldman, MD, MSCAI, FACC, FESC; and Shakeel A. Qureshi, MD, FRCP, FRCPCH
Complicated Radial Access During Primary PCI
By Moderator: Pieter C. Smits, MD, PhD, FESC
Panel: Mohamed Abdel-Wahab, MD, FESC; Peter W. Danse, MD; and Valeria Paradies, MD
Peripheral Vascular Programs Could Improve Population Health and Grow Volumes
An overview of the steps involved in developing a PAD program to address this underserved patient population.
